Skip to content

Total Recall: Lateral Habenula and Psychedelics in the Study of Depression and Comorbid Brain Disorders

Matas Vitkauskas, Ajay S. Mathuru

International Journal of Molecular Sciences September 7, 2020 DOI: 10.3390/ijms21186525 via OpenAlex

Summary

AI-generated from the abstract

Depression affects millions worldwide. Recent research explores the lateral habenula's role in depression and the potential of psychedelics like psilocybin and ketamine as treatments. Clinical trials are testing deep brain stimulation of the habenula and psychedelic therapies targeting the serotonergic system. Early results are promising but require cautious optimism; more animal studies in naturalistic settings, larger human trials with better neuroimaging, and understanding of genetic and molecular factors underlying comorbid disorders are needed. Advances in cerebral organoids may accelerate progress. This review covers developments in these areas and discusses future directions.

Study at a glance

Characteristics Review Peer reviewed
Topics Psilocybin Serotonin
Keywords Habenula Neuroscience Neuroimaging
Citations 4
Key finding Research into the lateral habenula and psychedelics shows promise for treating depression, but more evidence from animal and human studies is needed.

Abstract

Depression impacts the lives and daily activities of millions globally. Research into the neurobiology of lateral habenula circuitry and the use of psychedelics for treating depressive states has emerged in the last decade as new directions to devise interventional strategies and therapies. Several clinical trials using deep brain stimulation of the habenula, or using ketamine, and psychedelics that target the serotonergic system such as psilocybin are also underway. The promising early results in these fields require cautious optimism as further evidence from experiments conducted in animal systems in ecologically relevant settings, and a larger number of human studies with improved spatiotemporal neuroimaging, accumulates. Designing optimal methods of intervention will also be aided by an improvement in our understanding of the common genetic and molecular factors underlying disorders comorbid with depression, as well as the characterization of psychedelic-induced changes at a molecular level. Advances in the use of cerebral organoids offers a new approach for rapid progress towards these goals. Here, we review developments in these fast-moving areas of research and discuss potential future directions.

Explore topics

Comments

No comments yet.

Log in to comment